Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy.pdfVIP

SAGE-Hindawi Access to Research Journal of Osteoporosis Volume 2011, Article ID 810697, 4 pages doi:10.4061/2011/810697 Case Report Bilateral Femoral Insufficiency Fractures Likely Related to Long-Term Alendronate Therapy Ravindra Gudena, Jason Werle, and Kelly Johnston Department of Orthopedics, University of Calgary, 711B, 3607-49 ST NW, Calgary, Alberta, Canada T3A 2H3 Correspondence should be addressed to Ravindra Gudena, gudenar@ Received 4 November 2010; Accepted 8 March 2011 Academic Editor: David L. Kendler Copyright © 2011 Ravindra Gudena et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Osteoporosis-related fractures are a major public health problem and one in two women and one in four men are affected with osteoporosis-related fractures. Alendronate (Fosamax) is one of the first bisphosphonates used to treat osteoporosis effectively. Recently, however, there is a concern regarding long bone insufficiency fractures related to long-term alendronate therapy. We report a case of bilateral femoral insufficiency fractures likely related to long-term alendronate therapy, the classic symptoms, signs, and treatment of these fractures. 1. Introduction with lumpectomy 10 years ago and has a history of well- controlled asthma, for which she did not require corticos- Osteoporosis-related fractures are a major public health teroid treatment. She had been receiving alendronate therapy problem mainly in postmenopausal women and the elderly. for post